Human peripheral blood mononuclear cells as a valuable source of disease‐related biomarkers: Evidence from comparative proteomics studies
PROTEOMICS – Clinical Applications · 2024-03 · 18 (2)
DOI: 10.1002/prca.202300072 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PROTEOMICS – Clinical Applications, online erschienen am 07.11.2023. Verfasst von Michal Alexovič und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovakia. Hauptthemen laut MEDLINE: Leukocytes, Mononuclear, Proteomics. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Research Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic, Slovak Research and Development Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic.
Abstract (Originalsprache)
Purpose
The discovery of specific and sensitive disease‐associated biomarkers for early diagnostic purposes of many diseases is still highly challenging due to various complex molecular mechanisms triggered, high variability of disease‐related interactions, and an overlap of manifestations among diseases. Human peripheral blood mononuclear cells (PBMCs) contain protein signatures corresponding to essential immunological interplay. Certain diseases stimulate PBMCs and contribute towards modulation of their proteome which can be effectively identified and evaluated via the comparative proteomics approach. Experimental design In this review, we made a detailed survey of the PBMCS‐derived protein biomarker candidates for a variety of diseases, published in the last 15 years. Articles were preselected to include only comparative proteomics studies.
Results
PBMC‐derived biomarkers were investigated for cancer, glomerular, neurodegenerative/neurodevelopmental, psychiatric, chronic inflammatory, autoimmune, endocrinal, infectious, and other diseases. A detailed review of these studies encompassed the proteomics platforms, proposed candidate biomarkers, their immune cell type specificity, and potential clinical application.
Conclusions
Overall, PBMCs have shown a solid potential in giving early diagnostic and prognostic biomarkers for many diseases. The future of PBMC biomarker research should reveal its full potential through well‐designed comparative studies and extensive testing of the most promising protein biomarkers identified so far.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovakia.
- Research Centre for Genetic Engineering and Biotechnology "Georgi D Efremov", Macedonian Academy of Sciences and Arts, Skopje, North Macedonia.
ORCID-Profile: Katarina Davalieva
Förderung
- Research Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic
- Slovak Research and Development Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic
Zitieren
APA
Alexovič, M., Uličná, C., Sabo, J., & Davalieva, K. (2024). Human peripheral blood mononuclear cells as a valuable source of disease‐related biomarkers: Evidence from comparative proteomics studies. PROTEOMICS – Clinical Applications, 18(2). https://doi.org/10.1002/prca.202300072
Vancouver
Alexovič M, Uličná C, Sabo J, Davalieva K. Human peripheral blood mononuclear cells as a valuable source of disease‐related biomarkers: Evidence from comparative proteomics studies. PROTEOMICS – Clinical Applications. 2024;18(2). doi:10.1002/prca.202300072
BibTeX
@article{Alexovi2024,
author = {Alexovič, Michal and Uličná, Csilla and Sabo, Ján and Davalieva, Katarina},
title = {Human peripheral blood mononuclear cells as a valuable source of disease‐related biomarkers: Evidence from comparative proteomics studies},
journal = {PROTEOMICS – Clinical Applications},
year = {2024},
volume = {18},
number = {2},
doi = {10.1002/prca.202300072}
}
EUVIMED